# Foundayo (Orforglipron): the GLP-1 Pill With No Fasting Rule

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-16 | Updated: 2026-11-10

Canonical page: https://glpwatchdog.org/research/foundayo-orforglipron-oral-glp1

> Approved April 1, 2026, as the second GLP-1 tablet for weight management, and the only one taken with or without food. It produced 11.1% weight loss at 72 weeks, below both injectable rivals. The label, the trials and the interactions.

## Key points

- NDA 220934, Eli Lilly, approved April 1, 2026: the second GLP-1 pill for weight, after the Wegovy pill, and the only one with no fasting rule.
- −11.1% at 72 weeks on the 17.2 mg dose vs −2.1% placebo; 71.5% lost at least 5% of body weight.
- Below semaglutide (14.9%) and tirzepatide (20.9%), but those are separate trials, not a head-to-head.
- It runs through CYP3A4: a strong inhibitor holds you to 9 mg, and the label tells you to come off oral contraceptives.

Foundayo is a once-daily GLP-1 **pill** for weight management. It is the second one approved in the United States, after Novo Nordisk’s Wegovy pill in December 2025,[5] and the first with no fasting routine: you swallow it **with or without food**, and there is no needle involved at any point. Eli Lilly got it approved on **April 1, 2026**.[1] At its maximum dose it produced **11.1%** weight loss over 72 weeks.[2]

It is more convenient than anything else approved for this. It is also, on the numbers published so far, *less effective* than the injections it is being compared to, and that trade is the whole decision. [Foundayo and Mounjaro](https://glpwatchdog.org/compare/drugs/foundayo-vs-mounjaro) both come from Eli Lilly, and in separate trials the gap is wide: the tirzepatide in Mounjaro, sold for weight as Zepbound, reached −20.9% at 72 weeks in SURMOUNT-1,[4] while Foundayo reached −11.1% at 72 weeks in ATTAIN-1.[2]

## What was actually approved

*Foundayo on Drugs@FDA*

| Field | Record |
| --- | --- |
| Application | NDA 220934 |
| Sponsor | Eli Lilly and Company |
| Active ingredient | Orforglipron calcium |
| Approved | **April 1, 2026** |
| Form | Film-coated tablet, once daily |
| Strengths | Six tablets: 0.8, 2.5, 5.5, 9, 14.5 or 17.2 mg |

Who it is for, per the label: adults carrying obesity, or adults carrying excess weight who also have a condition connected to it. The approval covers both losing the weight and keeping it off over the long term, and it is explicitly conditioned on diet and exercise running alongside. The drug is approved as part of a program, not instead of one.[2] That pairing has support beyond the label: in [records from 98,261 veterans with type 2 diabetes](https://glpwatchdog.org/research/lifestyle-plus-the-drug), a GLP-1 plus healthy habits was linked to fewer heart events than either one alone. Stacking it with a second GLP-1 is not recommended.

It is **not approved for type 2 diabetes**. Lilly has submitted that indication to the FDA, and no decision has been announced.[8] The largest diabetes trial so far, ACHIEVE-4, was published in October 2026: in 2,749 people with type 2 diabetes at raised cardiovascular risk, followed for a median of two years, the rate of heart attack, stroke, cardiovascular death or unstable-angina admission on orforglipron fell within the trial's safety margin against insulin glargine (hazard ratio 0.84, 95% CI 0.59 to 1.20).[7] That establishes heart safety against an active comparator. It does not show heart protection, which a non-inferiority trial is not built to test. That is the main gap between [Ozempic and Foundayo](https://glpwatchdog.org/compare/drugs/ozempic-vs-foundayo) today: Ozempic is a diabetes drug with a proven heart benefit, a 26% cut in major cardiac events in SUSTAIN-6, while Foundayo has shown heart safety but not heart protection.

> **Why this is not just “Rybelsus for weight”.** Rybelsus is oral semaglutide, [a peptide](https://glpwatchdog.org/research/are-glp1-drugs-peptides) approved for type 2 diabetes, and [its weight loss at those doses is modest](https://glpwatchdog.org/research/rybelsus-for-weight-loss). It barely survives the gut, which is why its label demands an empty stomach, a small sip of water and a wait before eating. The Wegovy pill is the same molecule at higher strengths and carries the same routine: an empty stomach, up to 4 ounces of water, then 30 minutes before food, drink or other tablets.[11] The diabetes version, [the Ozempic pill](https://glpwatchdog.org/research/ozempic-tablets-explained), has the same rules. Orforglipron is a **non-peptide small molecule**. It does not need protecting from your digestion, so the label simply says with or without food. That is the innovation here, and it is a chemistry story rather than a dosing one.

## How well it works

Two placebo-controlled trials of 72 weeks each support the approval, and they were split by diabetes status. Trial 1 took 3,127 participants and deliberately excluded anyone with type 2 diabetes; Trial 2 enrolled the people Trial 1 turned away.[2] Running them separately is what makes the results readable, because diabetes changes how much weight these drugs shift.

*Weight change from baseline after 72 weeks (intent-to-treat)*

| Daily dose | Trial 1 (no diabetes) | Trial 2 (type 2 diabetes) |
| --- | --- | --- |
| Placebo | −2.1% | −2.5% |
| 5.5 mg | −7.4% | −5.1% |
| 9 mg | −8.3% | −7.0% |
| **17.2 mg** | **−11.1%** | **−9.6%** |

Averages hide the spread, so the responder figure is the more useful one: on the top dose in Trial 1, **71.5%** cleared the 5% threshold that counts as a clinically meaningful loss, where 26.8% did so on placebo.[2] The dose response is clean (more drug, more effect), and the benefit held across age, sex, race, ethnicity, starting BMI and blood sugar status.

## Against the injections and the other pill

*Approved weight-management results, non-diabetic populations*

| Drug | Route | Weight change | Trial |
| --- | --- | --- | --- |
| **Orforglipron** (Foundayo) | Daily tablet | −11.1% at 72 weeks | Trial 1, n=3,127 |
| Oral semaglutide 25 mg (Wegovy pill) | Daily tablet | −13.6% at 64 weeks | OASIS 4, n=307 |
| Semaglutide (Wegovy) | Weekly injection | −14.9% at 68 weeks | STEP 1, n=1,961 |
| Tirzepatide (Zepbound) | Weekly injection | −20.9% at 72 weeks | SURMOUNT-1, n=2,539 |

> **Four trials, run separately. Nobody has put these drugs against each other.** The protocols, sites, years and participants all differ, so read the table as indicative rather than as a ranking anyone has measured. The four are worth setting side by side only because all of them enrolled people *without* type 2 diabetes, so the populations are at least comparable. Only a direct trial settles it, and none in obesity has reported. The one pill-against-pill trial, [ACHIEVE-3](https://glpwatchdog.org/research/the-first-pill-versus-pill-trial), was run in type 2 diabetes and measured blood sugar, not weight.

With that caveat honored, the shape is hard to miss: Foundayo lands below both injections,[3][4] and below the Wegovy pill’s trial figure.[6] If you want the largest average weight loss on the market, the evidence still points at tirzepatide. If you will not or cannot inject, there are now two approved pills. The Wegovy pill posted the higher number in its own trial, roughly matching the shot ([Wegovy pill vs injection](https://glpwatchdog.org/research/is-the-pill-as-good-as-the-shot)); Foundayo is the one without the fasting routine. And 11.1% is a real clinical result, not a consolation.

## The boxed warning, read carefully

Foundayo carries the same boxed warning about thyroid C-cell tumors as the rest of the GLP-1 class, and it repays a careful read, because the label says something unusual.

> “Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents… While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined.”[2]
>
> — FDA label, FOUNDAYO — Boxed Warning

The rodent tumors that generated this warning for the class were not produced by this molecule. It is not active in those species, so the experiment could not have produced them either way. The warning is retained because the human question behind it remains open, not because orforglipron failed a test. Two groups are ruled out entirely regardless: anyone whose own history or whose family’s includes medullary thyroid carcinoma, and anyone with MEN 2.

## The interactions that are new

This is where being a small molecule cuts the other way, and it is the part most likely to be skipped. Injectable GLP-1s are peptides and largely sidestep liver enzyme interactions. Orforglipron does not. It runs through CYP3A4, so other drugs change its levels and it changes theirs.[2]

- **Strong CYP3A4 inhibitors.** Your ceiling becomes 9 mg a day rather than 17.2 mg. Ones that also block OATP1B should not be combined with it at all.
- **Strong CYP3A4 inducers.** Avoid them. With moderate ones, the drug may simply work less well, so response needs watching and the dose may have to climb.
- **Simvastatin.** Do not go above 20 mg once daily while you are on it.
- **Oral contraceptives.** The label directs users onto a non-oral method, or onto an added barrier method. This one is easy to miss, and expensive to miss.
- **Anything else you swallow.** Gastric emptying slows, and that can change how another tablet is taken up.

> **The contraception advice is not boilerplate.** The label warns the drug can harm a developing fetus, and it tells you to discontinue it once you learn you are pregnant. Put together a drug that must not continue into pregnancy and a contraceptive pill whose reliability it may undercut, and this becomes a conversation for before the first tablet rather than after. Our page on [GLP-1s and hormonal birth control](https://glpwatchdog.org/research/glp1-and-hormonal-birth-control) covers the mechanism, and [pregnancy and trying to conceive](https://glpwatchdog.org/research/glp1-pregnancy-and-trying-to-conceive) covers the rest.

## What people actually reported

Reported in at least 5% of people taking it: nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux, flatulence and **hair loss**.[2] Nausea ran 26–35% across the doses against 10% on placebo, and 5% of people stopped the drug because of gastrointestinal effects. The full dose-by-dose table, dropout rates and interaction numbers are on [Foundayo side effects](https://glpwatchdog.org/research/foundayo-side-effects).

The label also warns on acute pancreatitis, severe gastrointestinal reactions (not recommended with severe gastroparesis), acute kidney injury from volume depletion, hypoglycemia when combined with insulin or an insulin secretagogue, hypersensitivity reactions, diabetic retinopathy progression, and acute gallbladder disease. Our pages on [hair and muscle loss](https://glpwatchdog.org/research/glp1-hair-loss-and-muscle-loss) and [pancreatitis and gallbladder risk](https://glpwatchdog.org/research/glp1-pancreatitis-and-gallbladder-risk) go into those two in depth.

## What it costs, and what it does not cost

Lilly sells it directly through LillyDirect. The self-pay price is $149 a month for the 0.8 mg starting dose, $299 for 9 mg, and $349 for 14.5 or 17.2 mg, which drops to $299 if each refill is bought within 45 days.[9] Through December 31, 2026, the 2.5 mg dose is temporarily $149 instead of $199 and the 5.5 mg dose $199 instead of $299.[10] Unless Lilly extends the offer, those two doses go back to their regular prices in January.

In this register, 28 telehealth sellers list Foundayo at a published monthly price. Of those, 20 start at $149, and the highest starting figure is $750. Some of those figures fold in a membership or care fee and others leave it to be added, so the lowest tablet price is not always the lowest total. [Foundayo cost](https://glpwatchdog.org/research/foundayo-cost) puts each seller's price beside its fee.

> **Disclosure.** Among those sellers, Found, Sesame Care, ShedRx and SkinnyRx are partners we earn a commission from; the others are not. This article was written from the FDA record and the label, and the number that matters most in it (11.1% against 14.9% and 20.9%) is not flattering to the drug. Our policy is at [/disclosure](https://glpwatchdog.org/disclosure).

The channels differ in what you pay for. [LillyDirect](https://glpwatchdog.org/reviews/lillydirect-foundayo) is Lilly’s own pharmacy channel and fills a valid prescription from any prescriber. [Walgreens Weight Management](https://glpwatchdog.org/reviews/walgreens-weight-management) and [Amazon One Medical](https://glpwatchdog.org/reviews/amazon-one-medical) charge for the visit and bill the medication separately, while [ZipHealth](https://glpwatchdog.org/reviews/ziphealth) adds a clinical service fee to each treatment. [PrideRx](https://glpwatchdog.org/reviews/priderx), an LGBTQ+-friendly service that sells only brand-name drugs, follows the visit-plus-drug pattern with a monthly membership, while LillyDirect bills the Foundayo itself.

[WeightWatchers](https://glpwatchdog.org/reviews/weightwatchers) bills Foundayo apart from its Med+ membership, with prescribing by [WeightWatchers Clinic](https://glpwatchdog.org/reviews/weight-watchers), whose care team works with commercial insurance. [Knownwell](https://glpwatchdog.org/reviews/knownwell), an obesity-medicine practice, bills insurance first and publishes its out-of-pocket prices. [Immortals](https://glpwatchdog.org/reviews/immortals) lists Foundayo tablets only in a three-month package paid up front. [ShedRx](https://glpwatchdog.org/reviews/shedrx) lists Foundayo at $149 a month for new patients, paid to the pharmacy, and charges its own $125 monthly membership and provider fee on top.

Two more things matter beyond the cash price. Foundayo is one of the drugs covered under the [Medicare GLP-1 Bridge](https://glpwatchdog.org/research/medicare-glp1-bridge), which means a **$50 monthly copay** for eligible beneficiaries. And there is **no compounded version of it**, nor should there be: it is a new, on-patent, commercially available drug with no shortage, so anything sold to you as compounded orforglipron is not a legitimate compounded product. Our guide to [which GLP-1s can be compounded](https://glpwatchdog.org/research/which-glp1-can-be-compounded) explains why that line exists.

## Common questions

## Frequently asked questions

### What is Foundayo?

The brand name for orforglipron, a once-daily GLP-1 tablet from Eli Lilly, cleared under NDA 220934 on April 1, 2026. It is the second GLP-1 pill approved for weight management in the US, after the Wegovy pill, and the only one that can be taken with or without food. It is prescribed to people whose weight is high enough to qualify on its own or who carry a related condition alongside it. It is not approved for type 2 diabetes.

### How much weight do people lose on it?

Over 72 weeks, and it depends heavily on the dose you reach. Among participants without diabetes the top 17.2 mg dose averaged 11.1%, against 2.1% for placebo, and about seven in ten of that group cleared a 5% loss. The 9 mg dose managed 8.3% and the 5.5 mg dose 7.4%. Where type 2 diabetes was present the top-dose figure fell to 9.6%.

### Is it as good as Wegovy or Zepbound?

On the published numbers, no. Orforglipron reported 11.1% at 72 weeks, injectable semaglutide 14.9% in STEP 1 and tirzepatide 20.9% in SURMOUNT-1. The Wegovy pill reported 13.6% at 64 weeks in OASIS 4. Those are separate trials rather than a head-to-head comparison, so the gaps are indicative rather than measured. All four did study people without diabetes, though, and the ordering is consistent. What orforglipron offers instead is a tablet with no food or water restrictions.

### Do I have to take it on an empty stomach?

No, and this is the practical advance over Rybelsus and the Wegovy pill, which must both be taken fasting. Orforglipron is a non-peptide small molecule rather than a peptide, so it does not need to be shielded from digestion. The label says once daily with or without food. Swallow the tablet whole, without breaking, crushing or chewing it, and never take more than one a day.

### How does the dose go up?

Slowly, and by design. You begin on the smallest tablet and hold there a full month before the next step, repeating that wait at every rung. There are six strengths in all, ending at 17.2 mg once daily. Whether you climb past the middle of the ladder depends on how you respond and what your stomach tolerates. The pace exists to blunt the nausea, which is why pushing it faster tends to backfire.

### Why does it have a thyroid cancer warning if it did not cause tumors?

Because the unresolved question is about people, not rodents. The label is unusually explicit that this molecule is inactive in rats and mice and raised no tumors in them. It does act on the human receptor, though, and whether the effect seen across the class carries over to humans has never been settled. The warning marks that gap rather than a failed study. Anyone with MEN 2, or with medullary thyroid carcinoma in their own or their family's history, is excluded from taking it.

### Does it interact with other medications?

More than the injectables do, and for a structural reason: it is a small molecule cleared through CYP3A4, so it sits in traffic the peptides drive around. Drugs that block that enzyme strongly pull your ceiling down to 9 mg; drugs that induce it strongly are off the table; simvastatin is held to 20 mg; and anyone relying on a contraceptive pill is steered onto a different method or told to add a barrier. Slower gastric emptying can also alter how other tablets are taken up. Hand your prescriber the full list, including anything over the counter.

### Can I get compounded orforglipron?

No. It is newly approved, on patent, commercially available and not in shortage, so there is no lawful basis for compounding it. Anything marketed to you as compounded orforglipron is not a legitimate compounded preparation, whatever the seller calls it.

## References

1. U.S. Food and Drug Administration Drugs@FDA record for FOUNDAYO (orforglipron calcium), NDA 220934, Eli Lilly and Company — approval date, dosage forms and strengths. FDA Drugs@FDA. 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220934
2. Eli Lilly and Company FOUNDAYO (orforglipron) tablets — prescribing information: indications, boxed warning, dosage and administration, drug interactions, adverse reactions and clinical studies. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
3. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/
4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
5. Novo Nordisk FDA approves Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults. PR Newswire — company press release. 2025. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html
6. Wharton S, Lingvay I, Bogdanski P, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025. PMID: 40934115. https://pubmed.ncbi.nlm.nih.gov/40934115/
7. Klein KR, Wysham C, Tuttle KR, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. The Lancet. 2026. PMID: 42815506. https://pubmed.ncbi.nlm.nih.gov/42815506/
8. Eli Lilly and Company Lilly reports second-quarter 2026 financial results (Form 8-K, Exhibit 99.1) — regulatory progress includes the submission for orforglipron for type 2 diabetes in the U.S. U.S. Securities and Exchange Commission (EDGAR). 2026. https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/q226lillysalesandearningsp.htm
9. Eli Lilly and Company Foundayo self-pay pricing by dose — LillyDirect. LillyDirect. 2026. https://www.lilly.com/lillydirect/foundayo
10. Eli Lilly and Company Foundayo full terms and conditions — Journey Program and temporary self-pay prices through December 31, 2026. LillyDirect. 2026. https://www.lilly.com/lillydirect/foundayo/foundayo-full-terms-conditions
11. Novo Nordisk WEGOVY (semaglutide) injection and tablets — prescribing information: dosage and administration. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

---

Cite as: GLP Watchdog, Ruth Calder, "Foundayo (Orforglipron): the GLP-1 Pill With No Fasting Rule", published 2026-08-16, updated 2026-11-10. https://glpwatchdog.org/research/foundayo-orforglipron-oral-glp1

Canonical HTML page: https://glpwatchdog.org/research/foundayo-orforglipron-oral-glp1

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
